{
    "clinical_study": {
        "@rank": "137838", 
        "arm_group": [
            {
                "arm_group_label": "Control group", 
                "arm_group_type": "No Intervention", 
                "description": "Best Supportive care"
            }, 
            {
                "arm_group_label": "1-time injection group: Livercellgram", 
                "arm_group_type": "Experimental", 
                "description": "Within 1 month after extracting bone marrow, directly inject 5X107 autologous bone marrow-derived mesenchymal stem cells within liver through the hepatic artery."
            }, 
            {
                "arm_group_label": "2-time injection group: Livercellgram", 
                "arm_group_type": "Experimental", 
                "description": "Within 1 month after extracting bone marrow, directly inject 5X107 autologous bone marrow-derived mesenchymal stem cells within liver through the hepatic artery. Within 1 month after cell injection, re-inject autologous bone marrow-derived mesenchymal stem cells."
            }
        ], 
        "brief_summary": {
            "textblock": "If the participant voluntarily agrees to participate in the clinical trial before\n      registration, the investigator conducts a screening test to evaluate the participant's\n      suitability.\n\n      A participant that satisfies all selection and exclusion criteria is assigned randomly to a\n      test group (1-time or 2-time injection group) or control group (no-cell therapy group).\n      Participants assigned to the 1-time injection group conduct cell therapy within 1 month\n      after bone marrow aspiration. Before implementing cell therapy, implement hepatic artery\n      catheterization which inserts a catheter into the hepatic artery through the right aorta\n      femoralis and inject 5X107 autologous bone marrow-derived mesenchymal stem cells.\n      Participants assigned to the 2-time injection group store 1-time injection amount of\n      mesenchymal stem cells while being cultivated after sampled from the bone marrow, and will\n      re-inject autologous mesenchymal stem cells within 1 month after first injection.\n\n      Participants will make a total of 8 hospital visits on a 4-week interval after registration,\n      and effectiveness and safety will be evaluated based on a fixed procedure on every visit."
        }, 
        "brief_title": "REVIVE(Randomized Exploratory Clinical Trial to Evaluate the Safety and Effectiveness of Stem Cell Product in Alcoholic Liver Cirrhosis Patient)", 
        "condition": "Alcoholic Liver Cirrhosis", 
        "condition_browse": {
            "mesh_term": [
                "Liver Cirrhosis", 
                "Fibrosis", 
                "Liver Cirrhosis, Alcoholic"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Histologically or clinically diagnosed as alcoholic liver cirrhosis\n\n          2. Classified as Child-Pugh grade B or C\n\n          3. Age of 20 ~ 70 years\n\n          4. Capable of conducting hepatic artery catheterization which inserts a catheter up to\n             the hepatic artery\n\n          5. In the case of fertile women, confirmed as negative in pregnancy test when screening,\n             and agreed to avoid pregnancy during the trial period\n\n          6. Women capable of pregnancy must satisfy the following conditions; Has been through\n             menopause for at least 1 year, has no possibility of pregnancy via surgery/procedure,\n             or effectively used acceptable contraceptive methods (Intrauterine device-loop,\n             mirena, diaphragm or condom/femidom, oral contraceptive pills, non-oral\n             contraceptives)\n\n          7. Patient who can agree to participate in the clinical trial by oneself or by one's\n             legal representative\n\n          8. Able to conduct the clinical trial according to the protocol\n\n        Exclusion Criteria:\n\n          1. Diagnosed with malignant hematologic disease (acute myeloid leukemia, acute\n             lymphoblastic leukemia, non-Hodgkin lymphoma, Hodgkin lymphoma, multiple myeloma) and\n             not cured from it\n\n          2. Patient with severe aplastic anemia\n\n          3. Has a medical record of solid cancer(within 5 years prior to screening), or diagnosed\n             with solid cancer and currently receiving cancer treatment\n\n          4. Incapable of conducting hepatic artery\n\n          5. Patient who consumed alcohol and took hepatotoxic drugs within 6 months prior to\n             registration\n\n          6. Has continuously taken a large amount of steroids or antibiotics for 1 month prior to\n             registration\n\n          7. Judged by a researcher to have had major orthopedic surgery, organ biopsy, or similar\n             external injury within 3 months prior to registration\n\n          8. Evidence of active autoimmune liver disease\n\n          9. Patient with extrahepatic biliary stricture\n\n         10. Patient who conducted transjugular intrahepatic portosystemic shunt\n\n         11. Has active thrombosis of the portal or hepatic veins\n\n         12. Patient with sepsis\n\n         13. Patient who suffers heart, renal, respiratory failure\n\n         14. Patient who is positive in pathogenic test (HIV, Syphilis,HBV,HCV)\n\n         15. Pregnant or lactating woman\n\n         16. Patient who cannot adapt to the protocol and follow-up observation\n\n         17. Patient who has experienced drug abuse for the past 1 year\n\n         18. Participated in the other clinical trials within 30 days before registration\n\n         19. Patient with any disease or condition which the investigator feel would interfere\n             with trial or the safety of the subject"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "70 Years", 
            "minimum_age": "20 Years"
        }, 
        "enrollment": {
            "#text": "72", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "June 7, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_alias": "NCT01875211", 
            "nct_id": "NCT01875081", 
            "org_study_id": "PMC-BD-CT-P-002"
        }, 
        "intervention": {
            "arm_group_label": [
                "1-time injection group: Livercellgram", 
                "2-time injection group: Livercellgram"
            ], 
            "description": "Livercellgram\nDosage form and appearance: White cell suspension is filled in a clear plastic syringe, and fixed with an occlude on the prefilled syringe tip \u2461 Component: Autologous bone marrow-derived mesenchymal stem cell \u2462 Amount: 5X107 cells, 1-time or 2-time injection \u2463 Storage Method: Stored in airtight container at 20~25\u2103\nInjection Method: Directly inject into liver through hepatic artery", 
            "intervention_name": "Livercellgram", 
            "intervention_type": "Biological", 
            "other_name": "Autologous bone marrow-derived mesenchymal stem cell"
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "October 23, 2013", 
        "location": {
            "contact": {
                "email": "zzwan@pharmicell.com", 
                "last_name": "WanSeok Joo, Ph.D"
            }, 
            "contact_backup": {
                "email": "smpark@pharmicell.com", 
                "last_name": "Sunmi Park"
            }, 
            "facility": {
                "address": {
                    "city": "Seoul", 
                    "country": "Korea, Republic of"
                }, 
                "name": "Pharmicell Co., Ltd."
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Korea, Republic of"
        }, 
        "number_of_arms": "3", 
        "official_title": "Randomized Exploratory Clinical Trial to Evaluate the Safety and Effectiveness of Stem Cell Product in Alcoholic Liver Cirrhosis Patient.", 
        "overall_contact": {
            "email": "baiksk@yonsei.ac.kr", 
            "last_name": "Soon Koo Baik, M.D.,Ph.D"
        }, 
        "overall_contact_backup": {
            "email": "baesh@catholic.ac.kr", 
            "last_name": "Si-Hyun Bae, M.D.,Ph.D"
        }, 
        "overall_official": [
            {
                "affiliation": "Yonsei University, Wonju Christian Hospital", 
                "last_name": "Soon Koo Baik, M.D.,Ph.D", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "The Catholic University of Korea", 
                "last_name": "Si-Hyun Bae, M.D.,Ph.D", 
                "role": "Principal Investigator"
            }
        ], 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Korea: Ministry of Food and Drug Safety"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "January 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Histopathological evaluation (Fibrosis Grade - Laennec Scoring System)", 
            "safety_issue": "No", 
            "time_frame": "6 month after cell therapy"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01875081"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Histopathological evaluation score (Ratio of 1-time injection group to 2-time injection group comparison)", 
                "safety_issue": "No", 
                "time_frame": "6month"
            }, 
            {
                "measure": "MELD Score", 
                "safety_issue": "No", 
                "time_frame": "6month"
            }, 
            {
                "measure": "Child-Pugh grade", 
                "safety_issue": "No", 
                "time_frame": "6month"
            }, 
            {
                "measure": "Liver Function Test (ALT, AST, ALP, Albumin, billirubin, r-GT)", 
                "safety_issue": "No", 
                "time_frame": "6month"
            }, 
            {
                "measure": "Visual Inspection (Liver volume, Fibroscan)", 
                "safety_issue": "No", 
                "time_frame": "6month"
            }
        ], 
        "source": "Pharmicell Co., Ltd.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Pharmicell Co., Ltd.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "November 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "October 2013"
    }
}